莫米松

化合物

莫米松Mometasone),是一种糖皮质激素,用于治疗某些皮肤病花粉热哮喘[4] [5] [6],具体用于预防哮喘发作(非治疗)。[4]可应用于皮肤、吸入或鼻部。[4][5][6][7]

莫米松
临床资料
商品名英语Drug nomenclatureNasonex, Asmanex, Elocon, othersMometasone Use During Pregnancy. Drugs.com. 14 February 2020 [1 April 2020]. (原始内容存档于2020-10-26). </ref>
其他名称LAS-41002, 9α,21-Dichloro-11β,17α-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17α-(2-furoate)
给药途径Topical, inhalation (nasal spray)
药物类别英语Drug classCorticosteroid; Glucocorticoid
ATC码
法律规范状态
法律规范
药物动力学数据
生物利用度Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone[3]
血浆蛋白结合率98% to 99%
药物代谢Liver
生物半衰期5.8 hours
识别信息
  • (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
CAS号105102-22-5
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.125.600 编辑维基数据链接
化学信息
化学式C22H28Cl2O4 for mometasone
C27H30O6Cl2 as furoate
3D模型(JSmol英语JSmol
  • CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C

  • CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C
  • InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 checkY
  • Key:QLIIKPVHVRXHRI-CXSFZGCWSA-N checkY

  • InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
  • Key:WOFMFGQZHJDGCX-ZULDAHANSA-N

莫米松用于哮喘的常见副作用包括鹅口疮[4],因此建议使用后漱口,[4]长期使用可能会增加患青光眼白内障的风险。[4]应用于鼻部的常见副作用包括上呼吸道感染流鼻血[6]应用于皮肤时的常见副作用包括痤疮、皮肤萎缩和瘙痒。[5]它通过减少炎症起作用。[4]

糠酸莫米松于1981年获得专利,并于1987年开始医用。[8]它在世界卫生组织的基本药物清单上[9],可作为通用药物使用。 [10]2017年,它是美国第197种最常用的处方药,共开出超过200万张处方。[11] [12]

参考资料

  1. ^ Nasonex- mometasone furoate spray, metered. DailyMed. 26 January 2011 [19 June 2022]. (原始内容存档于2022-11-05). 
  2. ^ https://www.ema.europa.eu/documents/psusa/mometasone-list-nationally-authorised-medicinal-products-psusa/00002085/202005_en.pdf [裸网址]
  3. ^ Tayab ZR, Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ, Hochhaus G. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. British Journal of Clinical Pharmacology. November 2007, 64 (5): 698–705. PMC 2203259 . PMID 17509041. doi:10.1111/j.1365-2125.2007.02919.x. 
  4. ^ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Mometasone Furoate Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. (原始内容存档于2016-10-07) (英语). 
  5. ^ 5.0 5.1 5.2 Mometasone Furoate topical Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. (原始内容存档于2020-08-05) (英语). 
  6. ^ 6.0 6.1 6.2 Mometasone Furoate eent Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. (原始内容存档于2016-04-30). 
  7. ^ Mometasone. DrugBank. [30 April 2020]. (原始内容存档于2019-06-29). 
  8. ^ Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 488. ISBN 9783527607495. 
  9. ^ World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02. 
  10. ^ British national formulary : BNF 76 76. Pharmaceutical Press. 2018: 265. ISBN 9780857113382. 
  11. ^ The Top 300 of 2020. ClinCalc. [11 April 2020]. (原始内容存档于2020-03-18). 
  12. ^ Mometasone - Drug Usage Statistics. ClinCalc. [11 April 2020]. (原始内容存档于2021-01-27).